Screenpoint Medical
Founded 2014 · 85 employees on LinkedIn · 1 known investors
Find your way into Screenpoint Medical
25 people in our graph share verified history with the Screenpoint Medical team — schools, employers, funds. One of them is your warm intro.
Aina Cabrerounlockedknows Nico Karssemeijer · together at Leiden University
×11knows the team · via Leiden University
ScreenPoint Medical develops deep learning software for breast cancer detection, with its Transpara product providing AI-based analysis of 2D and 3D mammography acquisitions across major equipment manufacturers. It serves radiologists and breast imaging providers to support breast screening and diagnostic workflows.
Founders & leadership
Screenpoint Medical was founded in 2014 by Nico Karssemeijer and Sir Michael Brady.
NK.png?width=500&height=500&name=Nico_SPM_1%20(1).png)
Nico KarssemeijerinCo-Founder & Chief Scientific OfficerNico Karssemeijer holds a physics degree from Delft University of Technology and a graduate degree from Radboud University in Nijmegen. He spent decades in medical image analysis and computer-aided detection at Radboud University Medical Center's Department of Radiology, served as a consultant for breast cancer imaging companies including R2 Technology and U-Systems, and co-founded Volpara Health Technologies and QView Medical before co-founding ScreenPoint Medical in 2014.
SM
Sir Michael BradyCo-Founder; Emeritus Professor at University of Oxford
Investors · 1
Frequently asked questions
- What does Screenpoint Medical do?
- ScreenPoint Medical develops deep learning software for breast cancer detection, with its Transpara product providing AI-based analysis of 2D and 3D mammography acquisitions across major equipment manufacturers. It serves radiologists and breast imaging providers to support breast screening and diagnostic workflows.
- Who founded Screenpoint Medical?
- Screenpoint Medical was founded by Nico Karssemeijer, Sir Michael Brady in 2014.
- Who are Screenpoint Medical's investors?
- Screenpoint Medical's investors include Insight Partners.